Ketoconazole - ≥98%, high purity , CAS No.65277-42-1, Inhibitor of CYP3A4;Channel blocker of K v1.8

Item Number

K129737

• Synonyms: HMS3678J17 | Ketoconazole (k) | KTZ | MLS002222255 | N-(1,3,4-Trihydroxyoctadecan-2-yl)octadecanimidic acid | NCGC00025000-08 | SW196888-4 | ketoconazole | Opera_ID_397 | Prestwick0_000389 | NCGC00253967-01 | 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Potent cytochrome P450 inhibitor (K i values are 26.7 and 109 nM at CYP3A4 and CYP3A5, respectively). Antifungal agent. Additionally, shows activity at human androgen receptors.
• Storage Temp: Store at 2-8°C
• Shipped In: Wet ice
• Grade: Moligand™
• Action Type: CHANNEL BLOCKER, INHIBITOR
• Mechanism of action: Inhibitor of CYP3A4;Channel blocker of K v1.8
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Ketoconazole is an imidazole-containing small molecule inhibitor of cytochrome P-450-dependent steps in the biosynthesis of steroid hormones; also inhibits TXA Synthase (thromboxane synthetase) and 5-LO (5-lipoxygenase) activity. Ketoconazole exhibits antimetastatic, antineoplastic, and antipsoriatic activity. Inhibition of 5-LO (5-lipoxygenase) by Ketoconazole interrupts arachidonic acid -derived leukotriene production, which was correlated to a suppression of leukotriene-mediated anaphylactic bronchoconstriction in guinea pigs. Ketoconazole is described as reducing platelet cellular levels of thromboxane A2, suppressing thromboxane A2-mediated increase of microvascular permeability in response to ischemia insults. Ketoconazole produces an antiandrogen effect through inhibition of adrenocorticoid biosynthesis, suppressing the adrenal secretion of androgens and attenuating cortisol response. Ketoconazole is an inhibitor of CYP17A1, CYP3A4 and CYP3A5
An inhibitor of CYP proteins, thromboxane synthetase, and 5-LO